Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.

[1]  C. Marshall,et al.  The sevenmaker gain‐of‐function mutation in p42 MAP kinase leads to enhanced signalling and reduced sensitivity to dual specificity phosphatase action , 1994, FEBS letters.

[2]  C. Der,et al.  The Mitogen-activated Protein Kinase Phosphatases PAC1, MKP-1, and MKP-2 Have Unique Substrate Specificities and Reduced Activity in Vivo toward the ERK2 sevenmaker Mutation (*) , 1996, The Journal of Biological Chemistry.

[3]  Gerald R. Fink,et al.  MAP Kinases with Distinct Inhibitory Functions Impart Signaling Specificity during Yeast Differentiation , 1997, Cell.

[4]  E. Goldsmith,et al.  A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation , 1998, Current Biology.

[5]  Ming-Ming Zhou,et al.  Solution structure of ERK2 binding domain of MAPK phosphatase MKP-3: structural insights into MKP-3 activation by ERK2. , 2001, Molecular cell.

[6]  N. Ahn,et al.  Constitutive Activation of Extracellular Signal-regulated Kinase 2 by Synergistic Point Mutations* , 2001, The Journal of Biological Chemistry.

[7]  Bo Zhou,et al.  A Bipartite Mechanism for ERK2 Recognition by Its Cognate Regulators and Substrates* , 2003, Journal of Biological Chemistry.

[8]  E. Goldsmith,et al.  Docking motif interactions in MAP kinases revealed by hydrogen exchange mass spectrometry. , 2004, Molecular cell.

[9]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[10]  K. Resing,et al.  The gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity , 2006, Proceedings of the National Academy of Sciences.

[11]  Daryl A. Scott,et al.  Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development , 2007, Development.

[12]  N. Ahn,et al.  Isolation of Intrinsically Active (MEK-independent) Variants of the ERK Family of Mitogen-activated Protein (MAP) Kinases*♦ , 2008, Journal of Biological Chemistry.

[13]  Xiaoling Xie,et al.  Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. , 2009, Journal of medicinal chemistry.

[14]  O. Livnah,et al.  When expressed in yeast, mammalian mitogen-activated protein kinases lose proper regulation and become spontaneously phosphorylated. , 2009, The Biochemical journal.

[15]  W. Sellers,et al.  MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.

[16]  B. Taylor,et al.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner , 2010, Proceedings of the National Academy of Sciences.

[17]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[18]  J. Blenis,et al.  ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. , 2010, Molecular cell.

[19]  P. Crespo,et al.  Working Without Kinase Activity: Phosphotransfer-Independent Functions of Extracellular Signal–Regulated Kinases , 2011, Science Signaling.

[20]  R. Roskoski.  ERK1/2 MAP kinases: structure, function, and regulation. , 2012, Pharmacological research.

[21]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[22]  Rajiv Narayan,et al.  A melanocyte lineage program confers resistance to MAP kinase pathway inhibition , 2013, Nature.

[23]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[24]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[25]  David Tamborero,et al.  OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes , 2013, Bioinform..

[26]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[27]  Shuxia Zhao,et al.  Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.

[28]  Arul M Chinnaiyan,et al.  Translating genomics for precision cancer medicine. , 2014, Annual review of genomics and human genetics.

[29]  L. Garraway,et al.  ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. , 2014, Cancer research.

[30]  T. Mikkelsen,et al.  Comprehensive mutational scanning of a kinase in vivo reveals substrate-dependent fitness landscapes , 2014, Nucleic acids research.

[31]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[32]  Trevor J Pugh,et al.  Landscape of genomic alterations in cervical carcinomas , 2013, Nature.

[33]  Adam Godzik,et al.  e-Driver: a novel method to identify protein regions driving cancer , 2014, Bioinform..

[34]  Ken Chen,et al.  Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. , 2015, Cancer research.

[35]  E. Lander,et al.  Comprehensive assessment of cancer missense mutation clustering in protein structures , 2015, Proceedings of the National Academy of Sciences.

[36]  A. Reményi,et al.  Structural assembly of the signaling competent ERK2–RSK1 heterodimeric protein kinase complex , 2015, Proceedings of the National Academy of Sciences.

[37]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[38]  Pablo Tamayo,et al.  Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. , 2016, Cancer discovery.

[39]  Angela N. Brooks,et al.  High-throughput Phenotyping of Lung Cancer Somatic Mutations. , 2016, Cancer cell.

[40]  N. Ahn,et al.  Intrinsically active variants of Erk oncogenically transform cells and disclose unexpected autophosphorylation capability that is independent of TEY phosphorylation , 2016, Molecular biology of the cell.

[41]  Kristina Lorenz,et al.  Phosphorylation or Mutation of the ERK2 Activation Loop Alters Oligonucleotide Binding. , 2016, Biochemistry.

[42]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[43]  Li Ding,et al.  Protein-structure-guided discovery of functional mutations across 19 cancer types , 2016, Nature Genetics.

[44]  L. Zawel,et al.  Dissecting Therapeutic Resistance to ERK Inhibition , 2016, Molecular Cancer Therapeutics.